ReviewCancer imaging : the official publication of the International Cancer Imaging Society2025
Current evidence and strategies for preventing tumor recurrence following thermal ablation of papillary thyroid carcinoma.
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and efficacy of radiofrequency ablation for papillary thyroid carcinoma adjacent to the thyroid capsule.Frontiers in oncology · 2026Article
- Thermal field management in thyroid ablation for papillary thyroid carcinoma: Advancing precision and patient-centered care.World journal of radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe incidence of papillary thyroid carcinoma (PTC) has been increasing, and thermal ablation has emerged as a minimally invasive alternative to surgery for low-risk cases. However, post-ablation tumor progression remains a significant clinical challenge.
methodsThis review synthesizes existing literature on tumor progression after thermal ablation for PTC, analyzing potential causes and evaluating preventive strategies at different diagnostic and treatment stages.
resultsCurrent research reports indicate that the probability of disease progression following thermal ablation for PTMC ranges from 1.25 to 7.7%, a rate comparable to that of surgical management. Nodules exceeding 10 mm in diameter are associated with a higher risk of post-procedural progression. However, pathological evidence supporting these findings remains limited. Risk factors such as suboptimal patient selection and tumor proximity to critical structures further influence outcomes. Improved imaging guidance, standardized protocols, and stringent follow-up may reduce these complications.
conclusionWhen these recommendations are followed, thermal ablation for PTMC achieves effective reduction in tumor progression risk and represents a viable alternative for appropriately selected patients. However, expansion of its indications requires further robust evidence from large-scale, pathology-based studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.